Original Research Article

Application of an LC–MS/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study

Jaivik V. Shah\textsuperscript{a}, Jignesh M. Parekh\textsuperscript{a}, Priyanka A. Shah\textsuperscript{a}, Priya V. Shah\textsuperscript{a,b,c}, Mallika Sanyal\textsuperscript{b}, Pranav S. Shrivastav\textsuperscript{b,⁎}

\textsuperscript{a} Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad 380009, India
\textsuperscript{b} Department of Chemistry, St. Xavier's College, Navrangpura, Ahmedabad 380009, India
\textsuperscript{c} Department of Pharmacy, M. S. University, Pratapgunj, Vadodara 390002, India

A R T I C L E   I N F O

Keywords:
Amlodipine
Valsartan
Hydrochlorothiazide
LC–MS/MS
Polypill
Bioequivalence

A S T R A C T

A sensitive and selective method has been proposed for the simultaneous determination of amlodipine (AML), valsartan (VAL) and hydrochlorothiazide (HCTZ) in human plasma by liquid chromatography–tandem mass spectrometry (LC–MS/MS). The analytes and their deuterated analogs were quantitatively extracted from 100 μL human plasma by solid phase extraction on Oasis HLB cartridges. The chromatographic separation of the analytes was achieved on a Chromolith RP\textsubscript{18e} (100 mm × 4.6 mm) analytical column within 2.5 min. The resolution factor between AML and VAL, AML and HCTZ, and VAL and HCTZ was 2.9, 1.5 and 1.4, respectively, under isocratic conditions. The method was validated over a dynamic concentration range of 0.02–20.0 ng/mL for AML, 5.00–10,000 ng/mL for VAL and 0.20–200 ng/mL for HCTZ. Ion-suppression/enhancement effects were investigated by post-column infusion technique. The mean IS-normalized matrix factors for AML, VAL and HCTZ were 0.992, 0.994 and 0.998, respectively. The intra-batch and inter-batch precision (% CV) across quality control levels was ≤ 5.56% and the recovery was in the range of 93.4%–99.6% for all the analytes. The method was successfully applied to a bioequivalence study of 5 mg AML + 160 mg VAL + 12.5 mg HCTZ tablet formulation (test and reference) in 18 healthy Indian males under fasting. The mean log-transformed ratios of $C_{\text{max}}$, AUC\textsubscript{0-12h}, and AUC\textsubscript{0-inf} and their 90% CIs were within 90.2%–102.1%. The assay reproducibility was demonstrated by reanalysis of 90 incurred samples.

1. Introduction

Hypertension is considered as a major risk factor for an array of cardiovascular and related diseases, which is primarily responsible for the cause of death worldwide [1]. The biggest challenge in the treatment of hypertension is to effectively control the blood pressure (BP), using potent drug regimen with high efficacy and tolerability. Monotherapy is a rational therapeutic approach in patients with mild BP elevation and low-to-moderate cardiovascular risk. For uncontrolled BP levels, increase in dose strength in monotherapy is a rational alternative; however, several antihypertensive drugs including calcium antagonists have a dose-dependent tolerability profile. Thus, by increasing the dose strength there is an increased risk of adverse events which reduce patient compliance with therapy. In such a scenario, low-dose combination therapy with drugs having different and complementary mechanisms of action can substantially improve tolerability and at the same time minimize individual side effects [2].

Commonly available two-drug combinations have a renin secretion agent (beta blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker) and another component which is effective in renin-independent hypertension like diuretic, dihydropyridine or non-dihydropyridine calcium channel blocker. Based on these considerations, addition of a diuretic to a combination of an antagonist of the renin-angiotensin system and a calcium channel blocker can enhance the effect of other antihypertensive agents as well as benefit individuals with salt-sensitivity of BP [3]. One such fixed-dose combination therapy that has provided enhanced BP control is that of amlodipine (AML), a calcium channel blocker, valsartan (VAL), an angiotensin II receptor blocker and hydrochlorothiazide (HCTZ), a diuretic. This combination is available in the market as Exforge HCT®, containing 5/10 mg AML, 160/320 mg VAL and 12.5/25 mg HCTZ [4].

AML is a third-generation, long-acting dihydropyridine calcium channel antagonist, prescribed for the treatment of angina pectoris, hypertension, cardiac arrhythmias and coronary heart failure. It
inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. By acting as a peripheral arterial vasodilator, it reduces the peripheral vascular resistance, thereby lowering the blood pressure and relieving angina pain [3]. AML is extensively metabolized in the liver to inactive metabolites, with 10% of the parent drug and 60% of the metabolites excreted in the urine [4]. It is highly protein bound (98%), with a bioavailability of 60%–65%. AML has a long elimination half life in humans, ranging from 35 to 45 h due to the large volume of distribution (21 L/kg). Like most other dihydropyridine calcium channel blockers, it is used as a racemic mixture [5]. VAL is a potent, nonpeptide, highly selective and orally active antihypertensive drug belonging to the family of angiotensin II type I receptor antagonists. It has been used clinically for the treatment of hypertension and heart failure [6]. VAL is rapidly absorbed after oral administration, reaching peak plasma concentration within 2–4 h and has a terminal half life in the range of 3–7 h. It is extensively protein bound (~95%) and has an absolute average bioavailability of 23% for a capsule formulation and 39% for a buffered solution [7]. The thiazide diuretic HCTZ is responsible for reabsorption of electrolytes in the tubules of the kidney, facilitating an increase in the secretion of sodium and chloride and thereby leads to reduction in plasma volume. The antihypertensive activity of HCTZ begins within 2 h after oral administration and peaks at about 4 h [4].

Several methods are reported for the quantitation of AML alone [8–14], and in presence of other antihypertensive agents like metoprolol [15], nicardipine [16], telmisartan [17], bisoprolol [18], losartan [19] and benazepril [20] in plasma samples. Similarly, numerous bioanalytical methods are presented for the determination of VAL alone [21–23], in presence of drugs prescribed in cardiovascular therapy [24,25], along with other angiotensin II receptor antagonists [26–28]. Few other methods describe simultaneous determination of VAL and HCTZ [29,30] and VAL and AML in human plasma [31–33]. Likewise, several methods are described for the estimation of HCTZ as a single analyte [34,35] and together with other antihypertensive drugs [36–41] in biological fluids.

To the best of our knowledge, there are only four methods which describe their simultaneous analysis in pharmaceutical preparations [42,43] and human plasma [42–45]. The salient features of these methods are summarized in Table 1. Only one method presents the application of the method for pharmacokinetics in rats [45]. Moreover, there are no reports on the pharmacokinetics of polypill containing these drugs. Thus, the objective of this work was to develop and fully validate a selective and highly sensitive method for the simultaneous estimation of AML, VAL and HCTZ in human plasma by LC–ESI–MS/MS. The method presents an efficient extraction procedure based on solid-phase extraction with quantitative recovery for all the analytes. The sensitivity and overall analysis time is encouraging compared to previous reports [42–45]. The method is selective in quantifying AML, VAL and HCTZ in the presence of commonly prescribed cardiovascular drugs like losartan, telmisartan, candesartan, irbesartan and nifedipine. Systematic evaluation of matrix effect was done by calculating IS-normalized matrix factors and also by post-column infusion technique. The proposed method was successfully applied to a bioequivalence study of 5 mg (AML) + 160 mg (VAL) + 12.5 mg (HCTZ) fixed-dose combination (FDC) tablet formulation in 18 healthy Indian males under fasting.

2. Experimental

2.1. Chemicals and materials

Amlodipine besylate (AML, 99.50%) and amlodipine-d4 besylate (AML-d4, 99.10%) were purchased from SynFine Research Inc. (Ontario, Canada), valsartan (VAL, 99.80%) and valsartan-d9 (VAL-d9, 99.30%) were obtained from TLC Pharmachem Inc. (Ontario, Canada) and hydrochlorothiazide (HCTZ, 99.88%) and hydrochlorothiazide-13C,d2 (HCTZ-13C,d2, 99.29%) were procured from Clearsynth Labs Ltd. (Mumbai, India). HPLC grade methanol, acetonitrile, ammonium formate, formic acid and analytical reagent grade ammonia solution (30%) were obtained from Merck Specialties Pvt.
A Shimadzu LC-VP HPLC system (Kyoto, Japan) consisting of LC-10ADVP pump, SIL-HTc autosampler, CTO 10 Asvp column oven and a DGU-14A degasser was used for setting the reverse-phase liquid chromatographic conditions. The separation of AML, VAL and HCTZ was achieved on a Chromolith RP_{S} (100 mm × 4.6 mm) analytical column from Merck KGaA (Darmstadt, Germany) and maintained at 35 °C in a column oven. For isocratic separation, the mobile phase consisted of acetonitrile and 2 mM ammonium formate, pH 4.0 adjusted with formic acid (90:10, v/v). Ionization and detection of AML, VAL, HCTZ and ISs was carried out on a triple quadrupole mass spectrometer, MDS SCIEX API-4000 (Toronto, Canada), equipped with turbo ion spray interface and operated in positive ionization mode for AML and VAL and negative mode for HCTZ. The set chromatographic conditions and mass parameters are described in Supplementary material.

2.3. Calibrators and quality control samples

Calibration standards (CSs) were made at 0.02, 0.04, 0.10, 0.25, 0.50, 1.00, 2.50, 5.00, 10.0, and 20.0 ng/mL for AML, 5.00, 10.00, 50.0, 100.0, 200.0, 500.0, 1000, 2000, 5000 and 10,000 ng/mL for VAL and 0.20, 0.40, 1.00, 2.50, 5.00, 10.0, 25.0, 50.0, 100 and 200 ng/mL for HCTZ. Quality control (QC) samples were prepared at five levels, 16.0/8000/160 ng/mL (HQC, high quality control), 8.00/3500/ 80.0 ng/mL (MQC-2, medium quality control), 1.50/750.0/15.0 ng/mL (MQC-1, medium quality control), 0.40/150.0/4.00 ng/mL (LQC-2, low quality control), 0.06/15.00/0.60 ng/mL (LQC-1, low quality control) and 0.02/5.00/0.20 ng/mL (LLOQ QC, lower limit of quantification quality control) for AML/VAL/HCTZ, respectively. The details of solution preparation for analytes, ISs and their storage conditions are described in Supplementary material.

2.4. Extraction procedure

Prior to analysis, all frozen subject samples, calibration standards and quality control samples were thawed and allowed to equilibrate at room temperature. To an aliquot of 100 µL of spiked plasma sample, 25 µL of internal standard solution containing 1.0 µg/mL of each of was added and vortexed for 10 s. Furthermore, 400 µL of 1.0% formic acid was added and vortexed for another 10 s. The samples were loaded on Waters Oasis HLB (1 mL, 30 mg) extraction cartridges which were preconditioned with 1.0 mL of methanol followed by 1.0 mL of water. The cartridges were washed with 1.0 mL of MilliQ water followed by 1.0 mL of 10% methanol. Drying of cartridges was done for 2 min by applying 20 psi pressure. Elution of analytes and ISs from the cartridges was carried out with 1 mL of methanol and the eluate was evaporated to dryness in a thermostatically controlled water-bath maintained at 45 °C under a gentle stream of nitrogen gas. The dried samples were reconstituted in 100 µL of mobile phase solution and 5 µL was used for injection in the chromatographic system.

2.5. Validation procedures

Validation of the method was done for system suitability, selectivity, carryover, linearity, accuracy and precision, recovery, matrix effect, stability, dilution integrity and ruggedness as per the USPFD guidance [46] and was similar to that described in our previous work [47]. The detailed procedures are summarized in Supplementary material.

2.6. Bioequivalence study and incurred sample reanalysis

The validated method was successfully applied to quantify AML, VAL and HCTZ concentration in human plasma samples after oral administration of 5/160/12.5 mg respectively in FDC formulation. The design of the study comprised of “an open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover oral bioequivalence study for a FDC of 5/160/12.5 mg AML/VAL/HCTZ test (Indian Pharmaceutical Company) and a reference (Exforge HCT™) tablets distributed by Novartis Pharmaceuticals Corporation, New Jersey, USA) formulation in 18 healthy adult Indian males under fasting. The study was conducted as per the International Conference on Harmonization, E6 Good Clinical Practice guidelines [48]. Incurred sample reanalysis (ISR) was performed as discussed in our previous report [49]. The details for both the experiments are provided in Supplementary material.

3. Results and discussion

3.1. Method development

The present study was intended to develop a highly sensitive, selective and a high throughput method to determine AML, VAL and HCTZ in a single run for a clinical study involving healthy subjects. Due to significant difference in the ionization constants values of AML (pKa, 8.7) [50], VAL (pKa, 3.9 and 4.7) and HCTZ (pKa,7.9 and 9.2) [51], calibration range and their dose strength used in combination therapy, it was imperative to suitably optimize the extraction procedure, mass detection and the liquid chromatographic conditions for their simultaneous determination. During method development, electrospray ionization of the analytes and their deuterated analogs was carried out in the positive ionization mode for AML and VAL and negative mode for HCTZ. The set chromatographic conditions and mass parameters are described in Supplementary material.

The validated method was successfully applied to quantify AML, VAL and HCTZ concentration in human plasma samples after oral administration of 5/160/12.5 mg respectively in FDC formulation. The design of the study comprised of “an open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover oral bioequivalence study for a FDC of 5/160/12.5 mg AML/VAL/HCTZ test (Indian Pharmaceutical Company) and a reference (Exforge HCT™) tablets distributed by Novartis Pharmaceuticals Corporation, New Jersey, USA) formulation in 18 healthy adult Indian males under fasting. The study was conducted as per the International Conference on Harmonization, E6 Good Clinical Practice guidelines [48]. Incurred sample reanalysis (ISR) was performed as discussed in our previous report [49]. The details for both the experiments are provided in Supplementary material.

As evident from the methods listed in Table 1, only protein precipitation (PP) [42,44,45] and liquid-liquid extraction (LLE) [43] have been used to extract these drugs simultaneously from plasma samples. Thus, during initial trials these approaches were tested for selective extraction of the analytes using different solvent systems. PP was studied using methanol and acetonitrile as precipitants in 2:1 and 3:1 (v/v) with respect to the sample; however, the samples were not clear in either of the solvents with poor recovery for AML (18%) and
considerable ion suppression. LLE was then initiated with diethyl ether, dichloromethane, methyl tert-butyl ether (MTBE) and ethyl acetate under acidic (1.0%–5.0%, formic/acetic acid), basic (10–50 mM NaOH) and neutral conditions. Compared to other solvents, better results (66.5%–82.3%) were obtained with MTBE in presence of 5% formic acid for AML and VAL. However, the recovery was relatively poor for HCTZ (~22%) and inconsistent at all QC levels. Previous studies have reported use of Oasis hydrophilic–lipophilic balance (HLB) [10] and a monolithic weak cation exchange (WCX) column [16] for AML. Similarly, Oasis HLB [30] and Oasis mixed mode anion exchange (MAX) [28] have been employed for the extraction of VAL. Also, SPE on Oasis HLB has been used previously for quantitative recovery of HCTZ [39]. Thus, SPE was tried on Oasis HLB and also on MCX and MAX cartridges, which provide dual mode of retention (reversed-phase and ion-exchange) to have a reproducible and quantitative recovery with minimum matrix interference. Using the recommended Waters protocol for extraction of acidic and basic compounds, it was possible to separate AML (70%), HCTZ (66%) and VAL (37%) under acidic conditions of 5% formic acid on MCX cartridge. However, in presence of 5% NH₄OH the recovery was less for AML (51%) and HCTZ (56%) compared to VAL (73%) on MCX cartridge. Extraction on MAX cartridge resulted in much improved recovery for VAL (~85%), but was poor for AML (21%) and HCTZ (37%).

Thus, optimization of the sample clean-up procedure was done with HLB (1 mL, 30 mg) extraction cartridge to achieve satisfactory recovery for all the analytes, as it has hydrophilic and lipophilic sites. In addition to the difference in the ionization constants of the analytes, AML (logP = 2.6) and VAL (logP = 1.5) are relatively more lipophilic than HCTZ (logP = −0.07) [51,52]. These dissimilarities were effectively controlled on HLB instead of MCX or MAX extraction cartridges. The extraction was tried under acidic as well as neutral conditions on HLB cartridges. Precise and quantitative recoveries with minimum matrix interference were obtained in both the cases. However, due to comparatively higher recoveries in acidic (400 µL, 1.0% formic acid) media, the latter conditions were finalized in the present work.

Optimization of chromatographic conditions was equally critical for their adequate retention and simultaneous determination in a single run. This was thoroughly investigated by considering the column type, organic modifier, mobile phase composition (aqueous and organic part), buffer pH and strength, acidic and basic additives and flow rate. Based on this approach, the chromatographic separation was initiated by changing these parameters to achieve a short run time, symmetric peak shapes, minimum matrix interference and solvent consumption. Previous work on the simultaneous determination of AML, VAL and HCTZ have used different reversed-phase columns like Kinetex C₁₈ [42], ACE CN [43], Gemini C₁₈ [44] and Aquasil C₁₈ [45].

In all these methods, the analysis time was appreciably long (≥15 min) except for the work of Gadepalli et al. [45], in which it was 3.0 min. As a wide variety of columns with different dimensions (50–250 mm) have been reported for their simultaneous analysis, the chromatographic separation was tried initially on different columns like Inertsil ODS-3C₁₈ (50 mm × 4.6 mm, 3 µm), Phenomenex Gemini C₁₈ (100/150 mm × 4.6 mm, 5 µm), Waters X-Terra MS C₁₈ (100/150 mm × 4.6 mm, 5 µm), ACE C₁₈ (150 mm × 4.6 mm, 5 µm), Grace Kromasil C₁₈ (150 mm × 4.6 mm, 3.5 µm), Thermo Hypurity C₁₈ (100 mm × 4.6 mm, 5 µm) and Zorbax Eclipse XDB C₁₈ (150 mm × 4.6 mm, 5 µm). To find the best eluting solvent system, various combinations of methanol/acetonitrile along with buffers (ammonium formate/formic acid, ammonium acetate/acetic acid) having different ionic strengths (1.0–10 mM) in the pH range of 3.0–6.5 and volume ratios (70:30, 75:25, 80:20, 85:15, 90:10 and 95:05, v/v) were tested. Furthermore, the effect of flow rate was also studied from 0.5 to 1.1 mL/min, which was also responsible for acceptable chromatographic separation. In general, the use of methanol in the mobile phase resulted in broad peaks with considerable tailing and caused saturation in the response for higher calibration standards (CS-7 and CS-8) and at HQC level for VAL on majority of the columns except for X-Terra MS C₁₈ and Zorbax Eclipse XDB-C₁₈. Substituting methanol with acetonitrile gave much better chromatography; however, on some of these columns the run time was either too long (5–10 min) or too short (0.6–1.2 min) with very little retention for AML or VAL. Use of ammonium formate/acetate buffer having higher strengths (5.0–10 mM) did not help in obtaining linear response for calibration standards, especially for VAL. Similarly, flow rates above 0.8 mL gave inadequate resolution, while lower flow rate resulted in longer run time. Based on the outcome of these trials, further experiments were done on a highly porous monolith reversed phase column Chromolith RP_{18e} (100 mm × 4.6 mm) which is made from a single piece of high-purity polymeric silica gel. It has a unique combination of macropores and mesopores, which affords rapid flow of the mobile phase with minimum back pressure, at the same time, creates a uniform surface area for adsorption process, and thereby enhances the column performance. Two previous reports have successfully demonstrated the excellent performance of Chromolith columns for the simultaneous determination of AML with nicardipine [16] and VAL in combination with losartan and telmisartan [27]. After suitable optimization of chromatographic parameters on Chromolith RP_{18e}, it was possible to get the desired sensitivity, good linearity for the calibration curves, superior retention, resolution, run time and acceptable peak shapes. A mobile phase consisting of acetonitrile and 2 mM ammonium formate, pH 4.0 adjusted with formic acid (90:10, v/v), at a flow rate of 1.2 mL/min ensured baseline separation of AML, VAL and HCTZ at 1.80, 1.08 and 1.43 min respectively in a total run time of 2.5 min. The capacity factor (k) which shows the relative rates of migration of analytes on the column was 1.53, 0.52 and 1.01 for AML, VAL and HCTZ, respectively. The resolution factor between AML and VAL, AML and HCTZ, and VAL and HCTZ was 2.9, 1.5 and 1.4, respectively under isocratic conditions. The reproducibility of retention time for the analytes, expressed as % CV was ≤1.5% for 100 injections on the same column. The use of deuterated internal standards helped in maintaining the overall accuracy and precision of the method.

Fig. 1 shows representative chromatograms of the blank plasma, analytes at LLOQ level, real subject sample at C_{max} and their respective ISs. None of the antidepressant medications studied interfered in the determination of the analytes. Under the optimized experimental conditions, the retention time for losartan, telmisartan, candesartan, irbesartan and nifedipine was observed at 1.16, 1.31, 1.23, 1.28 and 1.54 min, respectively. However, due to their different MRM transitions, there was no interference in the quantification of the analytes. Results of post-column infusion experiment in Fig. S2 indicate no ion suppression or enhancement at the retention time of analytes and ISs. The IS-normalized matrix factor values ranged from 0.975 to 1.008, 0.965 to 1.014, and 0.979 to 1.018 for AML, VAL and HCTZ, respectively.

3.2. Method validation results

Carry-over evaluation was performed in each analytical run so as to ensure that it does not affect the accuracy and the precision of the proposed method. There was negligible carry over (<0.12%) observed during auto-sampler carryover experiment. No enhancement in the response was observed in extracted blank plasma (without ISs and analytes) after sub-sequent injection of highest calibration standard at the retention time of both analytes and ISs.

All five calibration curves were linear over the concentration range of 0.02–20.0 ng/mL for AML, 5.00–10,000 ng/mL for VAL and 0.20–200 ng/mL for HCTZ. The calibration lines were drawn using least square regression analysis to give the mean linear equation \( y = (1.0083 ± 0.0179)x − (0.0314 ± 0.0031) \), \( y = (0.9738 ± 0.0480)x − (17.6019 ± 13.1280) \) and \( y = (0.9760 ± 0.1239)x − (0.3104 ± 0.1875) \) for AML, VAL and HCTZ, respectively, where \( y \) is the peak area ratio of the analyte/IS and \( x \) the concentration of the analyte. The correlation
The coefficient \( (r^2) \) observed was \( \geq 0.9992 \), while the accuracy and precision (% CV) for the calibration curve standards ranged from 96.8% to 102.7% and 0.33%–6.36% respectively for all the analytes. The lowest concentration (LLOQ) in the standard curve that can be measured with acceptable accuracy and precision found was 0.02, 5.00 and 0.20 ng/mL for AML, VAL and HCTZ, respectively in plasma at a signal-to-noise ratio (S/N) of \( \geq 18 \).

The intra-batch and inter-batch precision and accuracy were established from validation runs performed at HQC, MQC-1/2, LQC-1/2 and LLOQ QC levels (Table S1). The intra-batch precision (% CV) ranged from 1.30% to 5.56% and the accuracy was within 96.9%–102.3% for all three analytes. Similarly, for the inter-batch experiments, the precision varied from 0.57% to 3.75% and the accuracy was within 96.7%–102.4%.

The relative recovery and IS-normalized matrix factors for AML, VAL, and HCTZ at LQC-1/2, MQC-1/2 and HQC levels are presented in Table 2. The relative recovery of the analytes is the ‘true recovery’, which is unaffected by the matrix as it is calculated by comparing the area ratio response (analyte/IS) of extracted (spiked before extraction) and unextracted (spiked after extraction) samples. Furthermore, the relative matrix effect, which compares the precision (% CV) values of the slope of the calibration curves prepared in different lots (sources) of plasma samples, was 3.08, 1.55 and 2.67 for AML, VAL and HCTZ, respectively as shown in Table S2.

The stability of analytes and ISs in human plasma and stock solutions was examined under different storage conditions. Samples for short-term stability remained unchanged up to 74 h, while the long-term stability of the stock solutions for analytes and ISs were stable for minimum of 132 days at 5 °C. AML, VAL and HCTZ in control human plasma (bench top) were stable for at least 28 h at 25 °C and for minimum of six freeze and thaw cycles at \(-20^\circ\)C and \(-70^\circ\)C. Spiked plasma samples stored at \(-20^\circ\)C and \(-70^\circ\)C, for long-term stability experiment were found stable for a minimum period of 132 days.

Autosampler stability (wet extract) of the spiked quality control samples maintained at 5 °C was determined up to 52 h without significant loss of the analytes. The percentage change for different...
Table 3
Stability of amlodipine, valsartan and hydrochlorothiazide in plasma under various conditions (n = 6).

| Storage conditions | QC Level | Nominal conc. (ng/mL) | Mean stability samples (ng/mL ± SD) | Change (%) |
|--------------------|----------|-----------------------|-------------------------------------|------------|
|                    |          | AML | VAL | HCTZ | AML | VAL | HCTZ | AML | VAL | HCTZ |
| Bench-top stability | HQC      | 16.0 | 8000 | 160.0 | 16.2 ± 0.54 | 7968 ± 94.7 | 159.7 ± 1.68 | 1.13 | -0.40 | -0.18 |
| at 25 °C, 30 h       | LQC-2    | 0.400 | 150.0 | 4.00  | 0.402 ± 0.008 | 146.0 ± 6.53 | 4.08 ± 0.15 | 0.50 | -2.65 | 1.90 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.059 ± 0.002 | 15.09 ± 0.33 | 0.601 ± 0.018 | -1.37 | 0.60 | 0.13 |
| Freeze and thaw      | HQC      | 16.0 | 8000 | 160.0 | 15.9 ± 0.38 | 7903 ± 83.4 | 156.5 ± 3.37 | -0.86 | -1.21 | -2.18 |
| stability at -20 °C  | LQC-2    | 0.400 | 150.0 | 4.00  | 0.384 ± 0.021 | 148.6 ± 4.25 | 3.83 ± 0.21 | -3.95 | -0.91 | -4.38 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.061 ± 0.001 | 14.66 ± 0.17 | 0.611 ± 0.012 | 2.17 | -2.30 | 1.89 |
| Freeze and thaw      | HQC      | 16.0 | 8000 | 160.0 | 15.7 ± 0.23 | 7883 ± 88.7 | 157.3 ± 1.80 | -1.63 | -1.46 | -1.66 |
| stability at -70 °C  | LQC-2    | 0.400 | 150.0 | 4.00  | 0.386 ± 0.009 | 142.0 ± 5.73 | 3.89 ± 0.08 | -3.50 | -5.36 | -2.85 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.061 ± 0.002 | 14.50 ± 0.33 | 0.613 ± 0.001 | 1.67 | -3.32 | 2.17 |
| Wet extract stability| HQC      | 16.0 | 8000 | 160.0 | 15.7 ± 0.47 | 8091 ± 135.9 | 163.0 ± 5.15 | -2.19 | 1.14 | 1.86 |
| at 2–8 °C, 56 h      | LQC-2    | 0.400 | 150.0 | 4.00  | 0.408 ± 0.017 | 152.8 ± 4.17 | 4.09 ± 0.20 | 2.05 | 1.89 | 2.32 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.058 ± 0.003 | 14.80 ± 0.41 | 0.583 ± 0.018 | -2.67 | -1.34 | -2.80 |
| Long-term stability  | HQC      | 16.0 | 8000 | 160.0 | 16.5 ± 0.34 | 8105 ± 90.4 | 162.4 ± 1.50 | 3.00 | 1.31 | 1.50 |
| at -20 °C, 132 days | LQC-2    | 0.400 | 150.0 | 4.00  | 0.409 ± 0.006 | 154.9 ± 2.27 | 4.16 ± 0.12 | 2.15 | 3.25 | 3.95 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.057 ± 0.002 | 15.42 ± 0.22 | 0.579 ± 0.012 | -5.00 | 2.81 | -3.46 |
| Long-term stability  | HQC      | 16.0 | 8000 | 160.0 | 16.2 ± 0.35 | 7914 ± 298.3 | 164.6 ± 4.38 | 1.44 | -1.07 | 2.89 |
| at -70 °C, 132 days | LQC-2    | 0.400 | 150.0 | 4.00  | 0.422 ± 0.007 | 151.7 ± 1.27 | 3.85 ± 0.15 | 5.50 | 1.16 | -3.72 |
|                     | LQC-1    | 0.060 | 15.00 | 0.600 | 0.059 ± 0.001 | 15.14 ± 0.16 | 0.605 ± 0.009 | -1.90 | 0.95 | 0.87 |

AML: amlodipine; VAL: valsartan; HCTZ: hydrochlorothiazide; SD: standard deviation.

stability experiments in plasma at two QC levels varied from ~5.36% to 5.50% for the analytes as shown in Table 3.

The dilution integrity experiment was performed with an aim to validate the dilution test to be carried out on higher analyte concentration above the upper limit of quantification (ULOQ), which may be encountered during real subject sample analysis. However, none of the subject samples measured showed concentration above the ULOQ. The precision (CV) for dilution integrity of 1/5th and 1/10th was between 1.42% and 2.69%, while the accuracy results were within 97.1% and 102.8% respectively for all the analytes, which are within the acceptance limit of 15% for precision (% CV) and 85%–115% for accuracy.

Method ruggedness was evaluated using re-injection of analyzed samples on two different batches of the same stationary phase and also with different analysts. The precision (% CV) and accuracy values for two different columns ranged from 1.0% to 2.5% and 98.5% to 103.5% respectively at all five quality control levels. For the experiment with different analysts, the results for precision and accuracy were within 1.7%–3.8% and 96.8%–101.5% respectively at these levels.

3.3. Application of the method and ISR results

The developed method was applied to enumerate the plasma concentration of AML, VAL and HCTZ for a bioequivalence study with a single fixed dose of a test and reference tablet formulation containing 5/160/12.5 mg AML/VAL/HCTZ in 18 healthy Indian male volunteers. The method was sufficiently sensitive to measure their concentration up to 120 h. Fig. 2 shows the plasma concentration-time profile of AML, VAL and HCTZ in human subjects under fasting condition after oral administration of FDC tablets. The mean pharmacokinetic parameters of the two formulations are summarized in Table 4. For a similar study in 30 healthy subjects with identical dose strength, the $C_{\text{max}}$, $\text{AUC}_{0\text{-inf}}$ and $T_{\text{max}}$ values were 2.7 ng/mL, 143.4 h·ng/mL and 6 h for AML, 3525 ng/mL, 26,327 h·ng/mL and 3 h for AML and 76.3 ng/mL, 517.6 h·ng/mL and 2 h for HCTZ, respectively [4]. Compared to the results obtained in the present work these values were somewhat lower for AML and VAL, while they were comparable for HCTZ. This can be attributed to difference in race, ethnicity and food, which may account for the observed differences in the pharmacokinetics of AML and VAL. The ratios of mean log-transformed parameters and their 90% confidence intervals for $C_{\text{max}}$, $\text{AUC}_{0\text{-120h}}$ and $\text{AUC}_{0\text{-inf}}$ were within the acceptance criterion of 80%–125%, proving that the test and reference formulations were pharmacokinetically equivalent in terms

Fig. 2. Mean plasma concentration-time profiles of (A) amlodipine, (B) valsartan and (C) hydrochlorothiazide after oral administration of 5 mg amlodipine besylate, 160 mg valsartan and 12.5 mg hydrochlorothiazide fixed dose tablet formulation to 18 healthy Indian males.
of rate and extent of drug absorption.

ISR was also conducted by random selection of 90 subject samples. The selection criteria included samples which were near the Cmax and the elimination phase in the pharmacokinetic profile of the drug [48]. The results obtained were compared with the data obtained earlier for the same sample using the same procedure. The percent change in the value was not more than ±15% (Fig. S3).

4. Conclusions

The proposed validated method for the simultaneous estimation of AML, VAL and HCTZ in human plasma is highly sensitive compared to all published reports. The method offers significant advantages over those previously reported, in terms of lower sample requirements (100 µL), simplicity of extraction procedure and overall analysis time. The efficiency of SPE and a chromatographic run time of 2.5 min per sample make it an attractive procedure in high-throughput bioanalysis of AML, VAL and HCTZ. The limit of quantification is low enough to monitor at least five half-lives of AML, VAL and HCTZ concentration with good intra- and inter-assay reproducibility (% CV) for the quality controls. The linear dynamic range established was adequate to measure the plasma concentration of AML, VAL and HCTZ in a clinical study involving Indian subjects. The proposed method is rugged and selective in presence of five cardiovascular drugs used in combination therapy. The reproducibility of study data was effectively demonstrated through ISR.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

One of the authors, Jaivik V. Shah, would like to acknowledge University Grants Commission, New Delhi, India, for BSR fellowship, F 4-1/2009 (BSR)/7-74/2007 and to the Department of Chemistry, Gujarat University, India, for carrying out this research.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jpha.2017.06.001.

References

[1] G. Mancia, G. De Backer, A. Dominiczak, et al., Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J. Hypertens. 25 (2007) 1105–1187.
[2] J. Schrader, A. Salvetti, C. Calvo, et al., The combination of amlodipine/valsartan 5/160 mg produces less pheripheraloedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg, Int. J. Clin. Pract. 63 (2009) 217–225.
[3] M. Destro, F. Cagnoni, A. D’Ospina, et al., Role of valsartan, amlodipine and hydrochlorothiazide fixed dose combination in blood pressure control: an update, Vasc. Health Risk Manag. 6 (2010) 253–260.
[4] E.D. Deeks, Amlodipine/valsartan/hydrochlorothiazide, fixed-dose combination in hypertension, Ann. J. Cardiovasc. Drugs 9 (2009) 411–418.
[5] K. McKenzie, M.A. Siddiqui, Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia, Am. J. Cardiovasc. Drugs 8 (2008) 51–67.
[6] M. Saydam, S. Taka, Bioavailability file: valsartan, Fasbad J. Pharm. Sci. 32 (2007) 185–196.
[7] M. Domenech, A. Coca, Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure, Patient Prefer. Adherence 4 (2010) 105–113.
[8] R.V.S. Nirgri, V.N. Kandikere, K. Mudigonda, et al., Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amloidipine in human plasma, Biomed. Chromatogr. 20 (2006) 833–842.
[9] Y. Ma, F. Qin, X. Sun, et al., Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry, J. Pharm. Biomed. Anal. 43 (2007) 1540–1545.
[10] J. Bhar, S. Singh, G. Subbaiah, et al., A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of amlodipine in human plasma, Biomed. Chromatogr. 21 (2007) 169–175.
[11] A. Sirisatkham, K. Panrat, N. Tanmanee, Determination of amloidipine in human plasma and its application in a bioequivalence study, J. Pharm. Biomed. Anal. 71 (2015) 863–867.
[12] I.A. Alsarra, High-performance liquid chromatographic method for quantitative determination of amloidipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies, J. Chromatogr. Sci. 47 (2009) 865–867.
[13] Q. Zou, Y. Zhan, Z. Ge, et al., Liquid chromatography-mass spectrometry method for the determination of amloidipine in human plasma and its application in a bioequivalence study, Xinzhengzhuyi Caijing 59 (2009) 383–391.
[14] J. Shenut, L. Pu, H. Zhou, et al., Determination of amloidipine in human plasma using automated online solid-phase extraction HPLC-tandem mass spectrometry: application to a bioequivalence study of Chinese volunteers, J. Pharm. Biomed. Anal. 70 (2012) 614–618.
[15] A.K. Sarkar, D. Ghosh, A. Das, et al., Simultaneous determination of metopropl succinate and amloidipine beylate in human plasma by liquid chromatography-tandem mass spectrometry method and its application to bioequivalence study, J. Chromatogr. B 873 (2008) 77–85.
[16] X. Wei, G. Yang, L. Qi, et al., Determination of nicardipine and amloidipine in human plasma using on-line solid-phase extraction with a monolithic weak cation-exchange column, Talanta 77 (2009) 1197–1202.
[17] V.R. Ravi, J.K. Inamadugu, N.R. Pilli, et al., Simultaneous determination of telmisartan and amloidipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study, J. Pharm. Biomed. Anal. 52 (2010) 319–326.
[18] H. Chang, J. Li, X. Guan, et al., Simultaneous determination of amloidipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study, J. Pharm. Biomed. Anal. 71 (2012) 104–110.
[19] V.K. Karra, N.R. Pilli, J.K. Inamadugu, et al., Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study, Pharm. Methods 3 (2012) 18–25.
[20] M.R. Rezk, K.A. Badr, Development, optimization and validation of a highly sensitive UPLC–EIS-MS/MS method for simultaneous quantification of amlodipine, benazepril and benazeprilat in human plasma: application to a bioequivalence study, J. Pharm. Biomed. Anal. 85 (2014) 1–8.
[21] J. Macze, J. Klima, P. Ptacek, Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography, J. Chromatogr. B 832 (2006) 169–172.
[22] N. Koski, H. Kawashita, H. Har, et al., Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal. 43 (2007) 1769–1774.
[23] C.Y. Lu, Y.M. Chang, W.L. Tseng, et al., Analysis of angiotensin II receptor antagonist and protein markers at microtiter level plasma by LC-MS/MS, J. Pharm. Biomed. Anal. 49 (2009) 123–128.

[24] G. Friarte, O. Gonzalez, N. Ferreiros, et al., Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy, J. Chromatogr. B 877 (2009) 3045–3053.

[25] O. Gonzalez, G. Friarte, N. Ferreiros, et al., Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drugs used in combined cardiovascular therapy in human plasma, J. Pharm. Biomed. Anal. 50 (2009) 630–639.

[26] N. Ferreiros, S. Dessen, R.M. Alonso, et al., Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression, Ther. Drug Monit. 29 (2007) 824–834.

[27] M.D.R. Brunetto, Y. Couteras, S. Clavijo, et al., Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence detection, J. Pharm. Biomed. Anal. 50 (2009) 194–199.

[28] M. Levi, G. Wuerzner, E. Ezan, et al., Direct analysis of valsartan and candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry, J. Chromatogr. B 877 (2009) 919–926.

[29] F. Liu, J. Zhang, Y. Xu, et al., Simultaneous determination of hydrochlorothiazide and valsartan in human plasma by liquid chromatography/tandem mass spectrometry, Anal. Lett. 41 (2008) 1348–1365.

[30] H.J. Shah, N.B. Kataria, G. Subbaiah, et al., Simultaneous LC-MS/MS analysis of valsartan and hydrochlorothiazide in human plasma, Chromatographia 69 (2009) 1055–1060.

[31] N.K. Ramadan, H.M. Mohamed, A.A. Moustafa, Rapid and highly sensitive HPLC and TLC methods for quantitation of amlodipine besilate and valsartan in bulk powder and in pharmaceutical dosage forms and in human plasma, Anal. Lett. 43 (2010) 570–581.

[32] A.V. Ramani, P. Sengupta, R. Mullangi, Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study, Biomed. Chromatogr. 23 (2009) 615–622.

[33] A.O. Alnajjar, Validation of a capillary electrophoresis method for the simultaneous determination of amlodipine besylate and valsartan in pharmaceuticals and human plasma, J. AOAC Int. 94 (2011) 498–502.

[34] D. Rajasekhar, J.J. Kumar, P. Venkateswarlu, High performance liquid chromatography/ negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study, Eur. J. Mass Spectrom. 15 (2009) 715–721.

[35] S.F. Pei, H. Guo, L.C. Zheng, et al., Determination of hydrochlorothiazide in human plasma by HPLC: application to a pharmacokinetic study, Lat. Am. J. Pharm. 33 (2014) 1470–1474.

[36] B. Singh, R.S. Lokhande, A. Dwivedi, et al., Improved simultaneous quantitation of candesartan and hydrochlorothiazide by human plasma by UPLC-MS/MS and its application in bioequivalence studies, J. Pharm. Anal. 4 (2014) 144–152.

[37] S. Koyuturk, N.O. Can, Z. Atkosar, et al., A novel dihete and shoot HPLC assay method for quantification of irbesartan and hydrochlorothiazide in combination tablets and urine using second generation C18-bonded monolithic silica column with double gradient elution, J. Pharm. Biomed. Anal. 97 (2014) 103–110.

[38] Z. Aydogmus, Simultaneous determination of aliskiren, amlodipine and hydrochlorothiazide in spiked human plasma and urine by high performance liquid chromatography, J. Anal. Chem. 70 (2015) 502–509.

[39] P.A. Shah, P. Sharma, J.V. Shah, et al., Simultaneous analysis of losartan, its active metabolite, and hydrochlorothiazide in human plasma by a UPLC-MS/MS method, Turk. J. Chem. 39 (2015) 714–733.

[40] J.R. Patel, T.M. Pethani, A.N. Vachhani, et al., Development and validation of bioanalytical method for simultaneous estimation of ramipril and hydrochlorothiazide in human plasma, J. Pharm. Anal. 7 (2017) 163–169.

[41] J.V. Shah, P.A. Shah, P.V. Shah, et al., Fast and sensitive LC-MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma, J. Pharm. Anal. 7 (2017) 163–169.

[42] S.M. El-Gizzawi, O.H. Abdelmaged, M.A. Omar, et al., Development and validation of HPLC method for simultaneous determination of amlodipine, valsartan, hydrochlorothiazide in dosage form and spiked human plasma, Am. J. Anal. Chem. 3 (2012) 422–430.

[43] S.E.K. Tekkeli, Development of an HPLC-UV method for the analysis of drugs used for combined hypertension therapy in pharmaceutical preparations and human plasma, J. Anal. Methods Chem. 2013 (2013) 179627.

[44] R.N. Sharma, S.S. Pancholi, Simple RP-HPLC method for the determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma, Acta Pharm. 62 (2012) 45–58.

[45] S.G. Gadepalli, P. Deme, M. Kanocha, et al., Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC-ESI-MS/MS and its application to pharmacokinetics in rats, J. Pharm. Anal. 4 (2014) 399–406.

[46] Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.

[47] J.V. Shah, D.P. Patel, P.A. Shah, et al., Simultaneous quantitation of atenolol and chlordiazepoxide in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry, Biomed. Chromatogr. 30 (2016) 208–216.

[48] Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biological Evaluation and Research (CBER), 1996.

[49] M. Yadav, F.S. Shrivastav, Incurred sample reanalysis: a decisive tool in bioanalytical research, Bioanalysis 3 (2011) 1007–1024.

[50] Novartis Pharmaceuticals Corporation, Exforge HCT® (amlodipine, valsartan, hydrochlorothiazide) tablets, Prescribing Information, East Hanover, New Jersey 07936, USA.

[51] Apotex Pty Ltd, APO-Valsartan HCTZ tablets, Product Information, 16 Giffnock Avenue, Macquarie Park NSW 2113.

[52] J.H. Patel, J.S. Patel, B.G. Desai, et al., Permeability studies of anti hypertensive drug amlodipine besilate for transdermal delivery, Asian J. Pharm. Clin. Res. 3 (2010) 31–34.